PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

Over the past few months, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) has been working on the advancement of its innovative Sol-gel drug delivery research program. The focus of the research is to apply Sol-gel technology to develop cannabinoid-based therapies for the relief of symptoms associated with pain, inflammation, seizures and neurological disorders.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.0503, up 44.96%, on 17,000 volume with 2 trades. The average volume for the last 60 days is 20,396 and the stock's 52-week low/high is $0.002/$0.20.

Recent News

• PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Continues Advancing Innovative Drug Delivery Research Program
• PreveCeutical Announces the Closing of Oversubscribed Non-Brokered Private Placement
• CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Develops Innovative Therapies as Alternative Medicine Market Surges

QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

Good tidings continue to grace the lithium industry, the latest being the 2018 report from British minerals analyst Roskill. After a recent market analysis, the British consultancy estimated that lithium demand from automotive applications, which reached over 34,000 metric tons of lithium carbonate equivalent (LCE) in 2017, will more than double by the end of the decade. Some of that demand could be satisfied by QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ).

QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.315, up 12.42%, on 34,150 volume with 18 trades. The average volume for the last 60 days is 119,118 and the stock's 52-week low/high is $0.0748/$1.46.

Recent News

• QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ) Reboots North American Lithium as Demand from Auto Industry Poised to Double
• NetworkNewsBreaks – QMC Quantum Minerals Corp. (TSX.V: QMC) (OTC: QMCQF) (FSE: 3LQ) Explores for Lithium at Cat Lake as Demand Continues to Rise
• NetworkNewsBreaks – QMC Quantum Minerals Corp. (TSX.V: QMC) (OTC: QMCQF) (FSE: 3LQ) Sees Great Potential in Irgon Lithium Mine Project Amid Demand Surge

Earth Science Tech, Inc. (OTC: ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech (OTC: ETST), an innovative biotech company, is now prototyping three cannabinoid-based (“CBD”) patent formulas. To view the full article, visit: http://cnw.fm/dMA08.

Earth Science Tech, Inc. (OTC: ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

• Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
• Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
• KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.80, up 0.80%, on 10,532 volume with 19 trades. The average volume for the last 60 days is 13,094 and the stock's 52-week low/high is $0.324/$1.62.

Recent News

• CannabisNewsBreaks – Earth Science Tech, Inc. (ETST) Aims to Help Prevent Cancer with Cannabinoid-based Products
• Earth Science Tech, Inc. Expands its Full Spectrum Cannabinoid (CBD) Chocolate Line with Three New Unique Products
• Earth Science Tech, Inc. Aligns with AATAC to Reach up to 90,000 Retail Outlets

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the results of the 2018 Annual General and Special Meeting. All motions were passed. Lexaria thanks its shareholders for their overwhelming support as the Company continues to make significant progress in pursuing its objectives.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $2.00, even for the day, on 45,540 volume with 90 trades. The average volume for the last 60 days is 273,153 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

• Lexaria Announces 2018 AGM Results and Corporate Update
• Lexaria Files New Patent Application for Enhancement of Delivery of Lipophilic Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System Disorders
• VIDEO: Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX)

ChineseInvestors.com (OTCQB: CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

Premier financial information company ChineseInvestors.com, Inc. (OTCQB: CIIX) recently entered a licensing partnership to redistribute popular interviews in the Chinese language. To view the full article, visit: http://cnw.fm/9Fnpy.

Founded in 1999, ChineseInvestors.com (OTCQB: CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.42, even for the day, on 6,701 volume with 8 trades. The average volume for the last 60 days is 53,839 and the stock's 52-week low/high is $0.40/$1.58.

Recent News

• CannabisNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Strengthens Focus on Being a Leader in Financial Information through Licensing Partnership
• ChineseInvestors.com, Inc.’s (CIIX) NewCoins168.com Website Offers ‘Live VIP’ Courses Focused on Investing in Cryptocurrencies
• ChineseInvestors.com, Inc. (CIIX) Set to Launch Bitcoin Trading Academy

Virtual Crypto Technologies Inc. (OTCQB: VRCP)

The QualityStocks Daily Newsletter would like to spotlight Virtual Crypto Technologies Inc. (VRCP).

CryptoNewsAudio announces the Audio Press Release (APR) titled "Cryptocurrency and Blockchain Innovators Poised to Reap Rewards as Fintech Reshapes How Money Is Used," featuring Virtual Crypto Technologies Inc. (OTCQB: VRCP). To hear the CryptoNewsAudio version, visit: http://ccw.fm/lj6iS. To read the original editorial, visit: http://ccw.fm/TVj3b. Also today, NetworkNewsWire released a report on the company detailing how VRCP’s NetoBit platform delivers high accuracy and cuts cryptocurrency transaction time by deploying its predictive algorithm. To view the full article, visit: http://nnw.fm/AtO9H.

Virtual Crypto Technologies Inc. (OTCQB: VRCP) is a developer of software and hardware for the purchase and sale of cryptocurrencies through ATMs, tablets, PCs and mobile devices. The company’s proprietary algorithmic technology trading platform, called NetoBit Trader, can instantaneously confirm the purchase or sale of Bitcoin, a process that typically can take between 10 minutes to 24 hours. All trades and exchanges are insured up to $3,000 per trade. The global cryptocurrency ATM market is predicted to surpass $285 million by 2025, yet, at present, only 30 percent of these machines allow two-way trades.

With NetoBit Trader, cryptocurrency holders enjoy immediate confirmation of Bitcoin and its crypto equivalents at the best crypto exchange rate at the point of transaction – providing a major breakthrough in the quest to bring cryptocurrencies to the mass market. Virtual Crypto’s cryptocurrency ATM, embedded with currency exchange transaction validation (CETV) in its hardware and software, accepts and dispenses cash and cryptocurrency in seconds.

Virtual Crypto’s NetoBit Trader and mobile retail point-of-sale platform incorporates advanced technologies tailored to the needs of primary market players, users, investors, and business owners. Virtual Crypto’s platform bridges the three main functions of the cryptocurrency sector – exchanges, wallets and payments – to the world of fiat exchanges, granting access to immediate cash exchanges between consumers and businesses worldwide.

NetoBit Trader’s over-the-counter, two-way transaction solution is available through one app, providing online cryptocurrency transactions at ecommerce and gaming portals. The app provides real-time cryptocurrency validation and exchange, easy buying and selling of Bitcoin with cash, enables traders to buy and trade crypto, and gamers to transfer cryptocurrency into cash after play. Crypto users can withdraw funds from their crypto accounts through a NetoBit cryptocurrency ATM or software-enabled tablet, and consumers can purchase retail with crypto from businesses that offer and use the NetoBit software.

The company’s newly redesigned corporate website, www.virtual-crypto.com, delivers a simple, clean design with enhanced functionality, features and navigation. Virtual Crypto’s new corporate website includes:

• Downloadable NetoBit Trader app link and contact forms for more information
• MarketWatch provides real-time tracking of the Bitcoin market, with other currencies to follow
• Improved security utilizing https certificates to protect personal information and site integrity
• Media room with downloadable product brochures, corporate presentations and other relevant content
• Investor’s page provides transparency to investors with direct access to Virtual Crypto’s progress through press releases, SEC filings, senior management team bios, and stock performance charts
• Social Media integration with buttons for LinkedIn, Twitter and Facebook jump to Virtual Crypto’s social media profiles, providing real-time updates from the online community

“Our primary objective is to make cryptocurrencies accessible to everyone, and that was the motivation for our redesign,” said Alon Dayan, Chief Executive Officer of Virtual Crypto. “The updated content provides real value for our customers, shareholders and employees, showcasing our products and services, in an intuitive, easy to navigate way.”

Virtual Crypto’s strategic vision of “Cryptocurrency Made Easy” allows crypto traders and users to overcome the complex hurdles currently hampering the cryptocurrency sphere.

Virtual Crypto Technologies Inc. (VRCP), closed the day's trading session at $0.14, even for the day, on 7,000 volume with 2 trades. The average volume for the last 60 days is 37,068 and the stock's 52-week low/high is $0.0125/$0.38.

Recent News

• CryptoNewsAudio Announces Audio Press Release (APR) on Virtual Crypto Technologies Inc. Clear Vision in Future of Fintech
• NetworkNewsBreaks – Virtual Crypto Technologies Inc.’s (VRCP) NetoBit Platform Significantly Speeds Up Cryptocurrency Transaction Times
• NetworkNewsAudio Announces Audio Press Release (APR) on Virtual Crypto Technologies Inc. Offers Compelling Solutions in Next-Gen Fintech Market

DeepMarkit Inc. (TSX-V: MKT) (OTCQB: MKTDF)

The QualityStocks Daily Newsletter would like to spotlight DeepMarkit Inc. (MKTDF).

Less than four months after launching its slide-out app “Gamify” for e-commerce websites, DeepMarkit Inc. (TSX.V: MKT) (OTCQB: MKTDF) announced that it has achieved an average of 61 percent month-over-month growth in its merchant base. Positive customer feedback and the onboarding of hundreds of new customers each month continues to energize DeepMarkit’s development team to create new features for its popular app.

DeepMarkit Inc. (TSX-V: MKT) (OTCQB: MKTDF), based in Calgary, Alberta, Canada, is a patent pending gamification technology company inventing new ways to engage consumers and other audiences. The Company’s proprietary promotions platform – “Gamify” – enables businesses and agencies to create branded games that incentivize consumers, thus driving sales, capturing data and generating leads. The DeepMarkit platform integrates next-gen gamification engagement mechanics with interactive advertising industry standards and powerful visuals, including 3-D images. Customers may choose from both free and paid solutions suitable for campaigns of all sizes, targeting multiple channels on the web, mobile and social media.

A team of seasoned, passionate gaming executives, led by president and CEO Darold Parken, has worked together for more than 15 years developing games and gaming systems that are still used today by some of the largest gaming companies in the world. This accomplished executive team founded Chartwell Technologies, acquired in 2011 by Amaya Gaming, which now is known as The Stars Group (Nasdaq: TSG) with a market cap of over $5 billion.

Gamify offers a selection of easily customizable gaming apps featuring a customer’s branded e-store in addition to tailored landing pages, technical support, real-time analytics, data collection and an engaging marketing campaign. Gamify’s patent-pending app comes complete with unique user incentives that draw consumers in with games and prizes, which in turn engages shoppers, turning them into buyers and building brand loyalty.

The gamification market is rapidly expanding and projected to be worth $22 billion by 2022, with a CAGR of 41 percent. DeepMarkit is the only publicly listed company focused solely on this exploding market that embraces any size of business, from the mom-and-pop shops to the blue-chip giants. DeepMarkit’s management team knows that increasing a customer’s conversion rate by a mere 1 percent has the potential to double revenue, which is why Gamify’s app and its ability to transform simple shoppers into engaged buyers is so compelling.

“Our marketing platform enables customers to build branded games that incentivize audiences, generate leads, and drive sales. Businesses need a way to stand out from the crowd,” Parken states in an investor’s video (https://www.youtube.com/watch?v=97hJoRKR92k). “DeepMarkit’s gamification platform gives customers that way to stand out and it’s a way that they can afford. That’s the strength of our platform. For a relatively small amount of money, any business can create a very powerful, high quality customer engagement using gamification.”

DeepMarkit recently entered into a joint marketing agreement with ITN International (“ITN”), a global leader in trade show data capture and analytics. The agreement will enable the 1.5 million exhibitors at the 125-plus yearly events serviced by ITN to purchase a customizable campaign with prize delivery and branded games that can be used in collaboration with ITN’s lead retrieval solutions. DeepMarkit and ITN are currently integrating DeepMarkit’s patent-pending gamification platform directly into ITN’s exhibitor portal.

“We started DeepMarkit because we have a passion for games and we believe in the power of games, not just for entertainment but more importantly as a tool for business,” Parken said. “DeepMarkit is a gamification company. What we mean by that is that we create innovative ways to use games for business purposes. Games to generate customer leads, games to promote products, deliver rewards, build brand awareness and customer loyalty.”

Selected as the winner of the New Company/Product pitch competition at the Retail Global 2017 Conference held in Las Vegas, Gamify’s platform has also attracted a $1.5 million investment from Allstate International LLC in Hong Kong. The investment gives Allstate a 10 percent stake in DeepMarkit and a great opportunity to bring the Gamify platform into the burgeoning Asian gaming market.

DeepMarkit Inc. (MKTDF), closed the day's trading session at $0.0364, even for the day. The average volume for the last 60 days is 37,389 and the stock's 52-week low/high is $0.0293/$0.12.

Recent News

• DeepMarkit Inc. (TSX.V: MKT) (OTCQB: MKTDF) Engages Consumers, Builds Merchant Base
• NetworkNewsBreaks – DeepMarkit Corp. (TSX-V: MKT) (OTCQB: MKTDF) Issues Business Development Update
• DeepMarkit Inc. (TSX.V: MKT) (OTCQB: MKTDF) is “One to Watch”

Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America Inc. (OTC: MCOA) is uniquely positioned to capture a substantial share of the industrial hemp market, offering increased value for its shareholders. To view the full article, visit: http://cnw.fm/HD0sa.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0353, off by 11.53%, on 10,585,963 volume with 270 trades. The average volume for the last 60 days is 7,303,573 and the stock's 52-week low/high is $0.0195/$0.0728.

Recent News

• CannabisNewsBreaks – Marijuana Company of America Inc. (MCOA) Focuses on Hemp Cultivation to Increase Shareholder Value
• CannabisNewsAudio Announces Audio Press Release (APR) on Marijuana Company of America Inc. Spearheading Efforts, Staking Claims in Hemp Cultivation
• Marijuana Company of America, Inc. (MCOA) Launches CBD Infused Facial Moisturizer through hempSMART™ Subsidiary

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF)

The QualityStocks Daily Newsletter would like to spotlight FinCanna Capital Corp. (FNNZF).

FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF) (“FinCanna”) a royalty company for the U.S. licensed medical cannabis industry, announces that it has closed its oversubscribed private placement previously announced on June 15 and upsized on June 18, 27 and 29, 2018.  The Company issued 20,396,535 Units at a price of $0.30 per unit for gross proceeds of $6,118,961. The Company anticipates some additional funds to be received within the week and will close these additional units at that time.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

Medical Cannabis Market

According to Ameri Research, the global market for licensed medical cannabis is growing at a compound annual growth rate (CAGR) of more than 21%, on track to exceed $63.5 billion by 2024. Within this market, FinCanna has identified considerable opportunity in California, the fifth largest economy in the world and the largest medical cannabis market in North America. Arcview Group forecasts California’s legal cannabis industry will grow at 21.1% CAGR to $6.5 billion in 2020, generating more than $1 billion in tax revenue.

Royalty Model & Portfolio

FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to debt and equity financing, allowing investees to maintain financial flexibility and control of their business rather than entering into arrangements that may include restrictive debt structures or giving up an ownership stake.

FinCanna’s portfolio includes Cultivation Technologies, Inc. (“CTI”), a team of experts from Fortune 150 agriculture, medical cannabis, law, engineering and technology companies. FinCanna is providing funding to CTI for its planned, fully entitled, large-scale indoor medical cannabis facility to be developed in Coachella, California.

CTI has established an interim medical cannabis extraction facility (the “Interim Facility”) that will produce licensed medical cannabis products until the Coachella Project is complete. CTI is currently expanding its product line, Coachella Premium, to include vaporizer cartridges. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

The Interim Facility can process up to 6,000 pounds of biomass per month, the equivalent of approximately 3.7 million grams of raw oil per year, with room for expansion. It is expected that the completed Coachella Project will be able to process 30,000 to 50,000 pounds of biomass per month, or the equivalent of 18 million grams to 30 million grams of raw oil per year.

Additionally FinCanna has entered into a royalty agreement with Green Compliance, a provider of point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

FinCanna has also signed binding term sheet with Oakland, California-based Gram Co Holdings, subject to due diligence by FinCanna. Gram Co is a cannabinoid research and refinement facility focused providing B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers, and numerous others in the cannabis supply chain. The company is also retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in 2018.

The foregoing contains forward-looking statements regarding Cultivation Technologies Inc. (“CTI”) which are subject to risks, uncertainties and contingencies which include, but are not limited to the statements relating the future construction and completion of the CTI medical cannabis facility in Coachella, California, and the projected biomass processing and raw oil production at the facility. Such forward looking statements are based on assumptions regarding the construction, completion and operations of CTI’s proposed facility, including that CTI will obtain the financing required to build and equip its proposed facility, that CTI will obtain the additional financing required operate the facility, that construction facility is completed on time and budget, that CTI obtains state licenses to operate on a permanent basis, and that the equipment used in the cultivation of medical cannabis performs at scale in a similar way it performs at CTI’s pilot tests.

FinCanna Capital Corp. (FNNZF), closed the day's trading session at $0.2259, off by 15.87%, on 127,044 volume with 43 trades. The average volume for the last 60 days is 38,893 and the stock's 52-week low/high is $0.10/$0.8736.

Recent News

• FinCanna Closes Oversubscribed Private Placement for $6.1 Million
• FinCanna Increases Private Placement to $6.1 Million
• Coverage Initiated for FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) via NetworkNewsWire

Zenosense, Inc. (OTC: ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO).

Healthcare technology company Zenosense (OTC: ZENO), through its joint venture ownership of MIDS Medical Limited (“MML”), is developing “MIDS”, a nano-magnetic detection technology to allow true laboratory accuracy at the point-of-care (“POC”). To view the full article, visit: http://nnw.fm/2fgYF.

Zenosense, Inc. (OTC: ZENO) (the “Company”) is a healthcare technology developer that participates in transformational, disruptive medical diagnostic projects; particularly handheld devices used at the Point of Care which are displacing slow and expensive laboratory tests.

Zenosense is primarily focused on the development and commercialization of MIDS Cardiac™ through the Company’s joint venture ownership in MIDS Medical Limited (“MML”). MIDS Cardiac is in development as a cost-effective, handheld Point of Care (“POC”) diagnostic device and disposable test strip for the early, rapid detection of suspected acute myocardial infarction (“AMI”, or “heart attack”).

Identification of very low levels of cardiac markers can significantly accelerate critical triage, diagnosis, treatment and disposition of patients reporting chest pain. Cardiac troponin is well documented as the preferred biomarker for diagnosis of AMI, with evidence continuing to demonstrate that high sensitivity troponin is the most powerful prognostic biomarker for the assessment of cardiovascular risk in the general population. However, highly sensitive troponin assays are currently available only on state of the art, central laboratory analyzers. These analyzers are extremely expensive, not generally available at the POC and slow to turnaround results (typically 60 minutes) when time is critical.

True, high-sensitivity devices are not available in smaller handheld devices at the POC, where they are most needed. This is because the optical detection systems generally used in central laboratory analyzers cannot be effectively miniaturized.

MIDS Cardiac uses the patented MIDS technology platform, exclusively available to MML. Instead of using conventional optical detection, MIDS can detect and quantify assay beads nano-magnetically. This means it can be incorporated in a small device expected to achieve highly sensitive detection levels, which can support true high sensitivity cardiac biomarker tests in emergency settings, at the POC.

Harnessing world-class expertise, the MML laboratory is located at the prestigious Sci-Tech Daresbury campus in the U.K., internationally recognized for leading-edge, scientific research and commercial development. MML has the sole rights to the MIDS technology platform, which is protected by patent applications already granted in China and the USA, and applications now in the national phase in all other key geographic areas.

MIDS Cardiac aims to provide a single troponin I or T test within 3 minutes and three panel assay (additional cardiac biomarkers) on a disposable test strip within 8 minutes, using a hand-held device costing a fraction of the price of laboratory analyzers.

MIDS Cardiac should only require a pin prick of blood for a single assay test carried out on an easy-to-use, disposable microfluidic test strip. MIDS Cardiac is being designed to be operated quickly by minimally trained personnel, producing a simple to interpret result in emergency settings, even in the back of an ambulance.

Initial testing of the electronic and microfluidic components of the MIDS Cardiac “Hybrid Strip” system was completed in November 2017. The Hybrid Strip system used for development testing aims to replicate as closely as possible a fully integrated Lab on Chip MIDS test strip set-up. Development testing was conducted on both the assembled hybrid unit and its electronic and microfluidic components separately, focusing mainly on the electronics of the magnetic sensing system.

Testing revealed that a variety of brands and sizes of commercially available assay beads could be magnetically detected in very low quantities, including samples of beads that were previously undetectable. In several instances, the current “limit of detection” appeared to already be at or near to the range advised by MML’s assay consultants as suitable for a high sensitivity troponin assay.

Dr. Nasser Djennati, MML’s Managing Director and Chief Scientific Officer, said; “These results come in at the very high end of detection expectations, even at this Hybrid Strip stage. As we move forward into true Lab on Chip construction, I expect detection levels to improve further still.”

Cardiovascular disease is the leading cause of death in the western world, accounting for more than 17 million deaths in Europe and the United States alone. Nearly 20 million patients each year visit an emergency room with reports of chest pain, with hundreds of millions spent on unnecessary admissions to the hospital. Zenosense Inc. is confident MIDS Cardiac will deliver unparalleled levels of accuracy, speed, reliability, ease of use and cost savings, making it the future device of choice for hospitals, emergency rooms, medical practitioners, paramedics and in low-resource settings.

The MIDS technology is also seen as having a far wider application, with the platform being capable of performing Point of Care immunoassay tests for a vast array of common healthcare concerns, a market projected to be worth $23.7 billion per year worldwide by 2019. The medical testing market as a whole is projected to be worth $53.34 billion by 2021. Zenosense believes the MIDS technology could be the most significant advance in diagnostic testing services in decades.

Zenosense, Inc. (ZENO), closed the day's trading session at $0.40, off by 2.44%, on 195,993 volume with 47 trades. The average volume for the last 60 days is 265,141 and the stock's 52-week low/high is $0.15/$0.895.

Recent News

• NetworkNewsBreaks – Zenosense, Inc. (ZENO) Poised to Capitalize on Fast-growing Market
• NetworkNewsBreaks – Zenosense, Inc. (ZENO) Developing Technology to Deliver High-sensitivity Laboratory Accuracy in Emergency Settings
• NetworkNewsAudio Announces Audio Press Release (APR) on Zenosense Demonstrating Impressive Results with MIDS Cardiac

GTX Corp. (OTC: GTXO)

The QualityStocks Daily Newsletter would like to spotlight GTX Corp. (GTXO).

GTX Corp. (OTC: GTXO) designs, manufactures and commercializes various products and services in the GPS tracking and monitoring business.  Operating domestically and internationally, via two subsidiaries engaged in the internet of things (IoT) and wearable technology industry. Founded in 2002 and headquartered in Los Angeles, California, the company is a pioneer in Smart GPS, cellular and Bluetooth Low Energy (BLE) tracking technology, offering complete, end-to-end tracking solutions through a proprietary IoT enterprise monitoring platform – the IoT Machine to Machine platform – backed by state-of-the-art hardware, software and connectivity solutions, patents and software algorithms.

Operating under the motto “We Put the ‘Where’ in Wearable Tech,” GTX’s main goal is to keep its customers connected to who and what matters most, with each of its patented tracking technologies providing real-time location coordinates on a map via a personalized portal. The company prides itself on offering not only technologies, but also effective solutions that provide safety, security and peace of mind by helping customers locate their loved ones or lost valuable items.

With a portfolio that includes more than 80 patents filed and issued and with products and services available in 35 countries, GTX’s tracking solutions use the latest in miniaturized, low-power GPS, mobile, RF and BLE technology, that can integrate seamlessly with multiple consumer products, enterprise and military applications. The company became a U.S. Military contractor in 2017 and is already developing asset and human tracking technology for the U.S. Air Force. Its list of customers also includes public health authorities and municipalities, emergency and law enforcement, NGOs, private companies, public and private senior care homes, and consumers.

The company’s flagship product is the award-winning GPS SmartSole®, the world’s first invisible wearable tracking device created specifically for people at risk of wandering, becoming lost or disoriented, including patients with Alzheimer’s, autism, dementia, traumatic brain injury and other cognitive problems. According to the World Alzheimer Report 2013 (http://nnw.fm/mrcV2), there are more than 100 million people worldwide who need constant care and monitoring because of a cognitive disorder, and their number is expected to rise to 277 million by 2050. Due to its hidden location – inside a shoe insert, the device can also be used by people undercover or at risk of kidnapping, such as government agents, military personnel, law enforcement, journalists, corporate executives, etc.

Other tracking devices designed and commercialized by the company for civilian or military use include:

• Take-Along Tracker 3G: A powerful mini-tracking device with GPS, 2G and 3G GSM data and voice capabilities, as well as a motion sensor and sleep mode. The device can be easily attached to a keychain, lanyard, dog collar, pocket, bag or plush toy for a discreet but advanced tracking solution.
• Invisabelt: Designed for children, this slim GPS tracker hidden inside a small waistband belt has a battery life of up to two days and is a great solution for parents who want to monitor their children’s location at all times.
• Track My Workforce: An easy and cost-effective solution that allows businesses to track and monitor their mobile workforce. The app is available for both Android and iOS systems, and allows employers to monitor their workforce from a single company account.
• E.T.S. -Personnel Equipment Tracking System: Currently in use at the Edwards Air Force Base, this tracking system allows real-time monitoring and surveillance of personnel and assets and has a 200+ square mile coverage. Solar powering capabilities and extend battery life allow the tracker to be used in areas without existing power sources.
• GPS Rifle Tracker: The company’s smallest GPS tracker, designed to withstand shocks and water submersion due to its robust, military standard enclosure, can be mounted on any AR15 platform picatinny rail to detect weapon discharge, track weapons and inventory, and send time and location alerts.

Led by a management team with solid experience in wearable technology, IoT, consumer electronics, mobile and technology licensing, as well as finance and the footwear industry, GTX plans to leverage its core technology platform to reach new verticals via licensing agreements and strategic partnerships, and to monetize its intellectual property portfolio. The monetization campaign kicked off in 2017 has already identified 100 companies that could become licensees. Besides military and law enforcement, the company also eyes the biometrics market, home health, medicare and insurance and other security applications for potential uses of its IoT platform and tracking technology.

GTX currently has 15 domestic and international distributors, subscribers in 35 countries and more than 700 online affiliates. With multiple revenue streams, several consecutive years of double-digit revenue growth and a strong pipeline of lucrative commercial products, GTX is uniquely positioned to become a leading provider of tracking solutions on this growing multi-billion-dollar market.

GTX Corp. (GTXO), closed the day's trading session at $0.0019, up 18.75%, on 718,968 volume with 12 trades. The average volume for the last 60 days is 5,405,724 and the stock's 52-week low/high is $0.0011/$0.0089.

Recent News

• GTX Corp Launches 2 New GPS Trackers for Kids SmartSole Now Available in Size Small
• GTX Corp. (GTXO) Details Advances in Wandering Tech and Strategic Plan to Uplist
• GTX Corp Announces Strategic Plan to Up-List to the OTCQB Venture Exchange

NUGL Inc. (OTC: NUGL)

The QualityStocks Daily Newsletter would like to spotlight NUGL Inc. (NUGL).

NUGL Inc. (OTC: NUGL), is a search engine and online directory for the marijuana industry. NUGL’s database includes listings for dispensaries, strains, doctors, lawyers, service professionals, vape shops, hydro stores and brands. The company focuses on leading the evolution in business relations, development and organic data in the cannabis industry with metasearch technology.

Headquartered in Chino Hills, California, which is home to a projected $5 billion legal marijuana marketplace, NUGL is on track to become a major asset for the global cannabis industry and related services sectors. The company recently established a strategic partnership with Thinklogic and appointed CEO Chris Adams to NUGL’s growing board of directors. Thinklogic is a top-level software development company specializing in projects for start-ups to Fortune 500 companies.

“This strategic partnership puts NUGL in a distinguished class, adding a first-rate technical software expert like Chris gives NUGL a unique technological advantage,” said Brandon Vargas CEO of NUGL. “With the addition of Chris’s knowledge and expertise combined with Thinklogics’ experienced and skilled staff, NUGL will have the ability to evolve and build a strong infrastructure unmatched in the 420 industry.”

NUGL is nearing completion of its initial launch timeline, with plans to launch the app on both Android and iOS platforms within the next few weeks. NUGL’s live testing of its software includes enhanced reviews that detail up to 10 category ratings. Each of the category rankings allow users to leave comments and choose among a 5-star rating among all categories or as few as they wish. The software’s rating platform allows for customization and transparency for users while providing invaluable feedback to shops and professional services.

“This is a major feature that is critical to our community,” said Jeff Odle, NUGL’s CTO. “Enhanced ratings will be a definitive difference validating our organic listings and raising the standard for the industry. We want the users to know what they are getting before they step into a store or sign up for a service.”

Leadership Team

NUGL is growing its team of developers and launching new features on an ongoing basis. The company is ahead of an impressive timeline, which includes building blocks for scalability and massive growth.

“Everything we do is focused on user experience. Our philosophy is simple – make it fun and easy to use, with the purest and most unbiased results,” said Ryan Bartlette, NUGL CMO. “As the industry evolves and becomes more sophisticated, NUGL will adapt and build the best marketing technology for the cannabis-related companies. We have gotten in on the ground level and know the pulse of the industry.”

NUGL CEO Brandon Vargas is a founding member of G6 Management, a full-service consulting firm advising cannabis professionals in all aspects of business. With over 10 years’ experience in the cannabis space, he has worked on dispensary, cultivation and infusion entity formation, licensing, real estate acquisitions, construction and build out, marketing, policy and procedures, compliance, staffing, and capital raises. Vargas has an extensive background working with various medical marijuana companies on investment and in developing greenhouse and commercial cultivation, distillate for vapes cartridges, CBD oils and infusions.

CMO Ryan Bartlette is co-founder and CMO of 23Forty LLC and Boxy. He has expertly positioned and branded many companies while bringing them to market and is a sought out graphic artist, front-end developer, photographer, and visual artist with experience in the entertainment and technology industry.

Jeff Odle, NUGL CTO, is a successful senior software architect has a long and distinguished career developing some of the most innovative, cutting-edge platforms available. His unique and distinctive approach to creating the blueprint for advanced programming is industry leading and unprecedented. He is a top-level architect responsible for developing some of the most forward-­looking software for various industries.

NUGL’s board of directors includes John R. Armstrong, a founding partner of Horwitz + Armstrong, a full service general business firm handling all aspects of litigation and business strategy and advice. Armstrong and his partner, Lawrence Hortwitz, have more than 10 years of experience in the cannabis space, representing cannabis professionals in all aspects of business including business formation, licensing, compliance with local and state regulations, real estate acquisitions, corporate mergers and acquisitions, financing, inclusive of capital raises and alternative financing, contracts, and all forms of dispute resolution.

Board member Hendrik Klein, founder of Da Vinci Asset Management, a privately-owned investment firm, serves as CEO and executive board member of Fritz Nols AG, a capital marketing consulting firm specializing in trading and asset management. Klein has received several industry awards including the Austrian Hedge Fund Award, the German Hedge Fund Award, and most recently was named the Global Best Performing Systematic Quantitative CTA. Klein and the Da Vinci team employ the latest quantitative data research and analysis in their innovative investment strategy.

NUGL Inc. (NUGL), closed the day's trading session at $1.12, up 0.90%, on 44,633 volume with 56 trades. The average volume for the last 60 days is 93,644 and the stock's 52-week low/high is $0.405/$1.80.

Recent News

• NUGL Launches iOS and Android Apps in iTunes and Google Play Stores
• CannabisNewsBreaks – NUGL Inc. (NUGL) Canada Legalizes Recreational Marijuana
• NUGL to Commence Audit of Financials and Move Forward with Up-Listing Requirements for OTCQB